Brief: Medicinova Says MN-166 And TMZ Combination Treatment Was Safe And Well-Tolerated, And No Unexpected Adverse Effects Were Reported

Medicinova

19/11/2023 23:04

Nov 19 (Reuters) - Medicinova Inc  MNOV.O :
    * MEDICINOVA ANNOUNCES NEW DATA AND RESULTS OF A PHASE 2
CLINICAL
TRIAL OF MN-166 (IBUDILAST) IN GLIOBLASTOMA PRESENTED AT THE
28TH ANNUAL MEETING OF THE SOCIETY FOR NEURO-ONCOLOGY
    * MN-166 (IBUDILAST) AND TMZ COMBINATION TREATMENT WAS SAFE
AND
WELL-TOLERATED, AND NO UNEXPECTED ADVERSE EFFECTS WERE REPORTED
    * MEDICINOVA - PRIMARY ENDPOINTS OF PHASE 2 CLINICAL TRIAL
WERE
SAFETY AND TOLERABILITY OF MN-166 (IBUDILAST), TEMOZOLOMIDE
(TMZ) COMBINATION TREATMENT
    * EFFICACY OF COMBINATION TREATMENT OF MN-166, TMZ  DEFINED
AS
PROGRESSION-FREE SURVIVAL RATE AT 6 MONTHS USING RANO CRITERIA

Source text for Eikon:  ID:nGNX5FpJ2P 
Further company coverage:  MNOV.O 

 ((Reuters.Briefs@thomsonreuters.com;;))